Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787910 | 0.92 | CA2 (0.75) | CA2ALDH1A1L3MBTL1TDP1NPSR1 | |
| SCHEMBL5537767 | 0.92 | CA2 (0.75) | CA2ALDH1A1L3MBTL1TDP1NPSR1 | |
| SCHEMBL15227905 | 0.89 | CA2 (0.58) | CA2ALDH1A1L3MBTL1TDP1NPSR1 | |
| SCHEMBL28789388 | 0.85 | CA2 (0.67) | CA2ALDH1A1L3MBTL1TDP1NPSR1 | |
| SCHEMBL13229 | 0.85 | CA2 (0.67) | CA2ALDH1A1L3MBTL1TDP1NPSR1 | |
| SCHEMBL13230 | 0.85 | CA2 (0.67) | CA2ALDH1A1L3MBTL1TDP1NPSR1 | |
| SCHEMBL12302088 | 0.84 | ALDH1A1 (0.67) | CA2ALDH1A1L3MBTL1TDP1NPSR1 | |
| SCHEMBL6290808 | 0.84 | CA2 (0.66) | CA2ALDH1A1L3MBTL1TDP1NPSR1 | |
| SCHEMBL13777927 | 0.84 | ALDH1A1 (0.67) | CA2ALDH1A1L3MBTL1TDP1NPSR1 | |
| SCHEMBL5540004 | 0.84 | ALDH1A1 (0.67) | CA2ALDH1A1L3MBTL1TDP1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008077194-A1 | RECEPTOR AGONISTS | XENOME LTD (AU) | 2008-07-03 | — | — | WO | claimed |
| WO-2023164476-A2 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20230127357-A1 | MIXED MODE CATIONIC EXCHANGE CHROMATOGRAPHY LIGANDS BASED ON SUBSTITUTED 2-BENZAMIDO ACETIC ACID STRUCTURES | BIO-RAD LABORATORIES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230127357-A1 | MIXED MODE CATIONIC EXCHANGE CHROMATOGRAPHY LIGANDS BASED ON SUBSTITUTED 2-BENZAMIDO ACETIC ACID STRUCTURES | BIO-RAD LABORATORIES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2023064949-A1 | MIXED MODE CATIONIC EXCHANGE CHROMATOGRAPHY LIGANDS BASED ON SUBSTITUTED 2-BENZAMIDO ACETIC ACID STRUCTURES | BIO-RAD LABORATORIES, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-1639080-A4 | A LIBRARY OF PHYLOGENETICALLY RELATED SEQUENCES | COGNETIX INC (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1639080-A2 | A LIBRARY OF PHYLOGENETICALLY RELATED SEQUENCES | Cognetix, Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004108901-A2 | A LIBRARY OF PHYLOGENETICALLY RELATED SEQUENCES | COGNETIX, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127357-A1 | MIXED MODE CATIONIC EXCHANGE CHROMATOGRAPHY LIGANDS BASED ON SUBSTITUTED 2-BENZAMIDO ACETIC ACID STRUCTURES | SSB, AEBP2, NASP | CA2 181/4885ALDH1A1 3112/4885L3MBTL1 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.